Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

TPST : 0.9411 (+3.49%)
Tempest Extends Limited Duration Stockholder Rights Plan

TPST : 0.9411 (+3.49%)
Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News

Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as it secured the U.S. Food and Drug Administration’s...

TPST : 0.9411 (+3.49%)
MarketBeat Week in Review – 10/16 - 10/20

All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control

HRL : 30.74 (-0.58%)
CPB : 46.38 (+0.11%)
LMND : 23.57 (-2.40%)
UAA : 8.64 (+1.41%)
VFS : 3.71 (-1.33%)
TSLA : 242.84 (-2.47%)
TXN : 203.66 (-0.61%)
META : 560.68 (-1.14%)
DLTR : 66.81 (+0.32%)
NFLX : 755.51 (-0.08%)
DXCM : 69.70 (-0.92%)
TPST : 0.9411 (+3.49%)
The Secrets Behind a 4000% Biotech Stock Surge

Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%.

TPST : 0.9411 (+3.49%)
Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)

Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week.

TPST : 0.9411 (+3.49%)
Navigating the Roller Coaster of Recent Penny Stock Surges

Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.

SECO : 0.4049 (+5.17%)
OPGN : 1.7500 (-3.18%)
TPST : 0.9411 (+3.49%)
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma

Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development

TPST : 0.9411 (+3.49%)
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets...

TPST : 0.9411 (+3.49%)
Tempest to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...

TPST : 0.9411 (+3.49%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings?
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar